newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 - - JTX-1484, a new antagonist antibody targeting LILRB4, enters IND-enabling activities representin